ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Jul 27th, 2021 - After acute leukemia and brain and central nervous system tumors, mature lymphomas represent the third most common cancer in pediatric patients. Non-Hodgkin lymphoma accounts for approximately 60% of lymphoma diagnoses in children, with the remain...

Jul 23rd, 2021 - Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare non-Hodgkin's lymphoma that arises as a single, or multiple dome-shaped tumours on the skin. The histology is characterised by the presence of atypical lymphocytes with large irr...

Jul 22nd, 2021 - A growing body of evidence indicates that breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is associated with the use of certain breast implants. Regional variations have been reported, and a genetic susceptibility has also been...

Jul 22nd, 2021 - Transcription factors Sox2 and Oct4 are essential in maintaining the pluripotency of embryonic stem cells and conferring stemness in cancer stem-like (CSL) cells. SORE6, an in-vitro reporter system, was designed to quantify the transcription activ...

Jul 20th, 2021 - Relapsed/refractory (R/R) classical HL (cHL) and systemic anaplastic large-cell lymphoma (sALCL) treatment options are limited in China and there is a need for new therapies. This single-arm, open-label, multicenter, Phase II study assessed effica...

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

Apr 13th, 2011 - The peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. Natural killer (NK) cell neoplasms are included in this group. The Wor...

Mar 4th, 2020 - This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with relapsed or refractory PTCL. The first 18 subjects may be of the following PTCL sub-types: PTCL not otherwise specified (PTCL-NOS), angioimm...

Feb 28th, 2020 - Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and ...

Feb 28th, 2020 - Although patients with ALK+ anaplastic large cell lymphoma (ALCL), a type of peripheral T-cell lymphoma (PTCL), are considered to have a favorable prognosis, relapse is not uncommon if multiple International Prognostic Index (IPI) risk factors, ag...

Feb 12th, 2020 - Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab

Jan 14th, 2020 - PRIMARY OBJECTIVE: I. Overall response rate (ORR) to single agent AT13387 (onalespib) as measured by the proportion of partial and complete responses (PR + CR) in patients with relapsed/refractory ALK positive (+) anaplastic large cell lymphoma (A...

Oct 14th, 2020 - NEW YORK (Reuters Health) - Using textured implants for reconstruction after mastectomy is associated with greater risk of breast cancer recurrence compared to smooth implants, according to new findings in JAMA Surgery. "We initiated this study fo...

Jul 10th, 2020 - The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large ce...

Jul 10th, 2020 - The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large ce...

Jul 9th, 2020 - As of April 2020, there have been 68 cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) reported in the UK. This figure includes cases where the original implantation did not occur in the UK. Based on the number of cases,...

Feb 13th, 2020 - The patient’s biopsy showed sparse and grouped and slightly enlarged atypical stained mononuclear cells in mostly perifollicular areas with focal epidermotropism. CD30 staining was positive.